Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Hepatocellular 4Liver Neoplasms 2Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Liver Diseases 1Hepatitis 1Glioblastoma 1Gastrointestinal Neoplasms 1Fibrosis 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Cisplatin 55Radiotherapy 33Cetuximab 25Paclitaxel 23Carboplatin 23Radiotherapy, Intensity-Modulated 21pembrolizumab 19Docetaxel 17Fluorouracil 16Nivolumab 14Drug Therapy 11Radiation 9Erlotinib Hydrochloride 8Blood Specimen Collection 8durvalumab 7Magnetic Resonance Spectroscopy 7Surveys and Questionnaires 6atezolizumab 5Surgical Procedures, Operative 5Radiosurgery 5Esophagectomy 5Chemoradiotherapy 5olaparib 4dacomitinib 4Leucovorin 4Cyclophosphamide 4Capecitabine 4Biopsy 4Afatinib 4fludarabine phosphate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Squamous Cell × bavituximab × Clear all
NCT04150900 2026-02-19

1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck

University of Maryland, Baltimore

Phase 2 Active not recruiting
7 enrolled 11 charts
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡